Lianjun Gao

Lianjun Gao


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2025 in Clinical Science
Verified
Journal Article
Open access
CLChao Li
Chao Li
XHXiao Han
Xiao Han
JHJiakang He
Jiakang He
STSheng-Xing Tang
Sheng-Xing Tang
YZYUNLONG ZHANG
YUNLONG ZHANG
LGLianjun Gao
Lianjun Gao
Heart failure with preserved ejection fraction (HFpEF) represents the initial phase of cardiac dysfunction associated with type 2 diabetes mellitus (T2DM). To date, the pathophysiological mechanisms underlying T2DM-induced HFpEF are complex and elusive. Fibroblast activation protein (FAP) is a prolyl-specific serine protease that its inhibition or vaccination has been shown to enhance cardiac repair following myocardial infarction (MI). However, the role and underlying molecular mechanisms by which abnormal FAP activity promotes the development of T2DM-induced HFpEF remain to be elucidated. In this study, the plasma activity and level of FAP were significantly higher in the T2DM with HFpEF group compared to the healthy control group. Moreover, plasma FAP activity and level were positively correlated with the likelihood of T2DM with HFpEF. To investigate the mechanistic involvement of FAP in the development of T2DM-associated HFpEF, a chronic T2DM mouse model was established. The results revealed that FAP KO significantly improved BNP level and E/A ratios compared to the WT T2DM group. Additionally, FAP KO and FAP inhibitor Talabostat alleviated myocardial inflammation, fibrosis, cardiomyocyte apoptosis, oxidative stress and energy metabolism dysfunction. Mechanistically, abnormal increase FAP triggered the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway, leading to the aforementioned pathological changes in T2DM-induced HFpEF. In contrast, FAP KO suppressed the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway and attenuated these pathological changes. Overall, these findings suggest that FAP may serve as a critical therapeutic target for T2DM-induced HFpEF.

1 May 2026 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
XMXiangzhu Meng
Xiangzhu Meng
YWYuhang Wen
Yuhang Wen
XWXiangying Wang
Xiangying Wang
THTesfaldet Habtemariam Hidru
Tesfaldet Habtemariam Hidru
YTYuqi Tang
Yuqi Tang
LGLianjun Gao
Lianjun Gao
Background: The uric acid-to-albumin ratio (UAR) is a novel inflammatory marker linked to cardiovascular disease. This study aimed to evaluate the predictive value of UAR for left atrial thrombus or spontaneous echo contrast (LAT/SEC) in non-valvular atrial fibrillation (NVAF), explore its mediating mechanisms, and assess the incremental value beyond the CHA2DS2-VASc score. Methods: This retrospective study included 514 patients with NVAF undergoing transesophageal echocardiography (TEE). Multivariable logistic regression, restricted cubic splines (RCS), generalized additive models (GAMs), receiver operating characteristic (ROC) curves, and mediation analyses were employed to evaluate the relationship between UAR and LAT/SEC. Reclassification indices assessed UAR’s incremental value beyond the CHA2DS2-VASc score. Results: The prevalence of LAT/SEC was 17.32%. UAR was independently associated with LAT/SEC (OR: 1.43, 95% CI: 1.25– 1.66; P < 0.001) in a nonlinear manner (P for non-linearity = 0.031). A threshold effect was identified at 12.11, below which the risk increased more significantly (OR: 1.61, 95% CI: 1.36– 1.92; P < 0.001). UAR showed better predictive performance (AUC=0.712) than UA (0.684) and albumin (0.612). Incorporating UAR into the CHA2DS2-VASc model improved risk stratification. Mediation analysis indicated that left atrial diameter (LAD) and left ventricular ejection fraction (LVEF) accounted for 8.26% and 9.75% of the association, respectively. Conclusion: UAR is an independent predictor of LAT/SEC in patients with NVAF, outperforming its individual components and providing significant incremental value beyond the CHA2DS2-VASc score. It may serve as a readily accessible biomarker for optimizing risk stratification and clinical anticoagulation decisions. Image A is an infographic with three sections: Study Population, Exposure and Outcome, linked by arrows. Study Population features a heart icon, ECG trace and five person icons, indicating 514 NVAF cases from 2019.1 to 2022.6. Exposure shows an arm with a blood draw and a marker icon, labeled UAR (uric acid/albumin). Outcome displays a heart icon, ECG trace and five person icons, noting 89 LAT/SEC cases in NVAF patients during admission. Image B is a dose-response graph with UAR on the X-axis and Odds ratio (95% CI) on the Y-axis. The curve rises with UAR and the 95% CI band widens at higher UAR. Text indicates P for overall < 0.001 and P for nonlinear = 0.031. Image C is a decision curve analysis graph with High Risk Threshold on the X-axis and Net Benefit on the Y-axis. The legend includes UAR + CHA2DS2-VASc, CHA2DS2-VASc, All and None. The UAR + CHA2DS2-VASc curve is generally above the CHA2DS2-VASc curve, both nearing zero at higher thresholds.A three-part infographic on NVAF: UAR exposure, LAT/SEC outcome and odds and decision-curve graphs.

11 November 2026 in Annals of Medicine
Verified
Journal Article
Open access
XMXiangzhu Meng
Xiangzhu Meng
YWYuhang Wen
Yuhang Wen
GZGe Zhan
Ge Zhan
YXYi Xia
Yi Xia
XWXiangying Wang
Xiangying Wang
LGLianjun Gao
Lianjun Gao
As the most common sustained cardiac arrhythmia in clinical practice, atrial fibrillation (AF) has a continuously rising global prevalence, particularly among the elderly, placing a substantial bur...